About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

Mini-Oral Presentation Details:

Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center

Session: Innovative Approaches to Key Molecular Targets

Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT

Location: Room S406 (Vista Ballroom)

Abstract Number: CT262

Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models

Presenter: John M. Maris, MD, Children’s Hospital of Philadelphia

Session: Advancing the Science of Childhood Cancers: From Bench to Bedside

Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT

Location: Room E353 C

Abstract Number: 1201

Poster Presentation Details:

Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

Presenter: Michal Zimmermann, PhD, Repare Therapeutics

Session: Cell Cycle Effects of Anticancer Drugs

Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT

Location: Poster Section 17

Poster Number: 9

Abstract Number: 365

Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors

Presenter: Anne Roulston, PhD, Repare Therapeutics

Session: Kinase and Phosphatase Inhibitors 1

Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT

Location: Poster Section 21

Poster Number: 9

Abstract Number: 1734

Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools

Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics

Session: Diagnostic Biomarkers 2

Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT

Location: Poster Section 31

Poster Number: 2

Abstract Number: 717

Title: Targeting CCNE1 amplification in gastric cancer

Presenter: Sung Joo Jang, Columbia University Irving Medical Center

Session: Protein Kinases and Phosphatases as Targets for Therapy

Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT

Location: Poster Section 24

Poster Number: 4

Abstract Number: 6942

A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

Contacts

Investor Relations & Media Contact:

Matthew DeYoung

Investor Relations and Media

Argot Partners

investors@reparerx.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.